NASDAQ:AQXP - Aquinox Pharmaceuticals Stock Price, Price Target & More

$13.00 +0.04 (+0.31 %)
(As of 04/26/2018 10:54 AM ET)
Previous Close$12.96
Today's Range$12.99 - $13.07
52-Week Range$10.02 - $16.90
Volume9,206 shs
Average Volume103,279 shs
Market Capitalization$295.52 million
P/E RatioN/A
Dividend YieldN/A
Beta-14.31

About Aquinox Pharmaceuticals (NASDAQ:AQXP)

Aquinox Pharmaceuticals logoAquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company's primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway. Its product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Company is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder. AQX-1125 is a SHIP1 activator that has demonstrated preliminary safety, anti-inflammatory potential and drug properties in multiple preclinical studies.

Receive AQXP News and Ratings via Email

Sign-up to receive the latest news and ratings for AQXP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AQXP
CUSIPN/A
Phone604-629-9223

Debt

Debt-to-Equity RatioN/A
Current Ratio9.94%
Quick Ratio9.94%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.21 per share
Price / Book3.09

Profitability

EPS (Most Recent Fiscal Year)($2.14)
Net Income$-50,180,000.00
Net MarginsN/A
Return on Equity-42.30%
Return on Assets-39.47%

Miscellaneous

Employees51
Outstanding Shares23,490,000

How to Become a New Pot Stock Millionaire

Aquinox Pharmaceuticals (NASDAQ:AQXP) Frequently Asked Questions

What is Aquinox Pharmaceuticals' stock symbol?

Aquinox Pharmaceuticals trades on the NASDAQ under the ticker symbol "AQXP."

How were Aquinox Pharmaceuticals' earnings last quarter?

Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) announced its quarterly earnings data on Monday, March, 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.59) by $0.10. View Aquinox Pharmaceuticals' Earnings History.

When is Aquinox Pharmaceuticals' next earnings date?

Aquinox Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Aquinox Pharmaceuticals.

What price target have analysts set for AQXP?

4 brokers have issued twelve-month target prices for Aquinox Pharmaceuticals' shares. Their predictions range from $22.00 to $28.00. On average, they expect Aquinox Pharmaceuticals' share price to reach $25.25 in the next twelve months. View Analyst Ratings for Aquinox Pharmaceuticals.

What are Wall Street analysts saying about Aquinox Pharmaceuticals stock?

Here are some recent quotes from research analysts about Aquinox Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada. " (3/16/2018)
  • 2. Cantor Fitzgerald analysts commented, "R&D day provided contemporary thoughts about IC/BPS and how rosiptor could address an unmet need. We attended an R&D day hosted by AQXP in NYC on Friday, Feb. 9 (presentation here). The company included Dr. Phillip Hanno (Clinical Prof, Stanford U.) on the program to provide a KOL viewpoint of interstitial cystitis/bladder pain syndrome (IC/BPS) and the treatment of it." (2/11/2018)
  • 3. Canaccord Genuity analysts commented, "We recently hosted a call with Dr. J. Quentin Clemens, chief of the Division of Neurourology and Pelvic Reconstruction, urology director for female pelvic medicine and professor of urology at the University of Michigan. While Dr. Clemens has not used AQXP’s rosiptor (AQX-1125), his discussion of IC/BPS provided us with more confidence in the design of the ongoing, pivotal Ph3 LEADERSHIP 301 assessing rosiptor in IC/BPS patients, which remains on track to complete enrollment in 1Q18 and for top-line data in 3Q18. We reiterate our BUY rating." (12/19/2017)
  • 4. Needham & Company LLC analysts commented, "Aquinox reported 3Q17 financial results this week. Phase 3 LEADERSHIP 301 trial of rosiptor continues to enroll pts and company continues to guide for top-line results in 3Q18. We expect a positive outcome based on Phase 2 data and reiterate BUY." (11/9/2017)

Who are some of Aquinox Pharmaceuticals' key competitors?

Who are Aquinox Pharmaceuticals' key executives?

Aquinox Pharmaceuticals' management team includes the folowing people:
  • David J. Main, Co-Founder, President and Chief Executive Officer and Chairman of the Board (Age 50)
  • Kamran Alam, Chief Financial Officer, Vice President - Finance (Age 40)
  • Lloyd Mackenzie, Chief Operating Officer, Vice President - R&D Operations (Age 48)
  • David Chilton Mitchell, Vice President - Global Regulatory Affairs & Quality Assurance (Age 59)
  • Barbara Troupin M.D., Chief Medical Officer, Vice President - Clinical Development (Age 48)
  • Robert E. Pelzer, Lead Independent Director (Age 63)
  • Gary J. Bridger Ph.D., Director (Age 52)
  • Daniel J. Levitt M.D., Ph.D., Director (Age 68)
  • Richard S. Levy M.D., Director (Age 59)
  • Kelvin M. Neu M.D., Director (Age 42)

Has Aquinox Pharmaceuticals been receiving favorable news coverage?

Media headlines about AQXP stock have trended positive recently, Accern reports. Accern ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aquinox Pharmaceuticals earned a daily sentiment score of 0.39 on Accern's scale. They also assigned headlines about the company an impact score of 47.17 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of Aquinox Pharmaceuticals?

Shares of AQXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aquinox Pharmaceuticals' stock price today?

One share of AQXP stock can currently be purchased for approximately $13.00.

How big of a company is Aquinox Pharmaceuticals?

Aquinox Pharmaceuticals has a market capitalization of $295.52 million. The company earns $-50,180,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis. Aquinox Pharmaceuticals employs 51 workers across the globe.

How can I contact Aquinox Pharmaceuticals?

Aquinox Pharmaceuticals' mailing address is 450-887 GREAT NORTHERN WAY, VANCOUVER A1, V5T 4T5. The company can be reached via phone at 604-629-9223 or via email at [email protected]


MarketBeat Community Rating for Aquinox Pharmaceuticals (AQXP)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  191 (Vote Outperform)
Underperform Votes:  129 (Vote Underperform)
Total Votes:  320
MarketBeat's community ratings are surveys of what our community members think about Aquinox Pharmaceuticals and other stocks. Vote "Outperform" if you believe AQXP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AQXP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Aquinox Pharmaceuticals (NASDAQ:AQXP) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Aquinox Pharmaceuticals in the last 12 months. Their average twelve-month price target is $25.25, suggesting that the stock has a possible upside of 94.23%. The high price target for AQXP is $28.00 and the low price target for AQXP is $22.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $25.25$25.25$25.00$24.6667
Price Target Upside: 94.23% upside64.92% upside117.77% upside72.98% upside

Aquinox Pharmaceuticals (NASDAQ:AQXP) Consensus Price Target History

Price Target History for Aquinox Pharmaceuticals (NASDAQ:AQXP)

Aquinox Pharmaceuticals (NASDAQ:AQXP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/11/2018Cantor FitzgeraldReiterated RatingBuy$28.00MediumView Rating Details
2/8/2018GuggenheimInitiated CoverageBuy -> Buy$26.00HighView Rating Details
12/19/2017Canaccord GenuitySet Price TargetBuy$22.00LowView Rating Details
11/9/2017Needham & Company LLCReiterated RatingBuy$25.00N/AView Rating Details
11/11/2016Leerink SwannReiterated RatingBuy$24.00N/AView Rating Details
8/5/2016Jefferies GroupBoost Price TargetHold$7.00 -> $9.00N/AView Rating Details
(Data available from 4/26/2016 forward)

Earnings

Aquinox Pharmaceuticals (NASDAQ:AQXP) Earnings History and Estimates Chart

Earnings by Quarter for Aquinox Pharmaceuticals (NASDAQ:AQXP)

Aquinox Pharmaceuticals (NASDAQ:AQXP) Earnings Estimates

2018 EPS Consensus Estimate: ($2.53)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.68)($0.68)($0.68)
Q2 20181($0.71)($0.71)($0.71)
Q3 20181($0.59)($0.59)($0.59)
Q4 20181($0.55)($0.55)($0.55)

Aquinox Pharmaceuticals (NASDAQ AQXP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018($0.70)N/AView Earnings Details
3/12/2018After Market($0.59)($0.69)ViewListenView Earnings Details
11/8/2017Q3 2017($0.62)($0.50)ViewN/AView Earnings Details
8/8/20176/30/2017($0.59)($0.59)ViewListenView Earnings Details
5/9/20173/31/2017($0.51)($0.36)ViewN/AView Earnings Details
3/9/201712/31/2016($0.51)($0.48)ViewListenView Earnings Details
11/9/2016Q316($0.58)($0.46)ViewN/AView Earnings Details
8/4/2016Q2($0.41)($0.63)ViewN/AView Earnings Details
5/10/2016Q1($0.35)($0.39)ViewN/AView Earnings Details
3/14/2016Q4 2015($0.38)($0.27)ViewN/AView Earnings Details
11/10/2015Q315($0.45)($0.43)ViewN/AView Earnings Details
8/6/2015Q215($0.56)($0.44)ViewN/AView Earnings Details
5/12/2015Q115($0.83)($0.60)ViewN/AView Earnings Details
4/15/2015($0.57)($0.78)ViewN/AView Earnings Details
3/16/2015Q4 2014($0.76)($0.78)ViewN/AView Earnings Details
11/4/2014Q3 2014($0.29)($0.59)ViewN/AView Earnings Details
8/11/2014Q2 2014($0.27)($0.51)ViewN/AView Earnings Details
5/13/2014Q1 2014($1.28)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Aquinox Pharmaceuticals (NASDAQ:AQXP) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Aquinox Pharmaceuticals (NASDAQ AQXP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.70%
Institutional Ownership Percentage: 91.48%
Insider Trading History for Aquinox Pharmaceuticals (NASDAQ:AQXP)
Institutional Ownership by Quarter for Aquinox Pharmaceuticals (NASDAQ:AQXP)

Aquinox Pharmaceuticals (NASDAQ AQXP) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/15/2018Lloyd MackenzieCOOSell1,302$14.63$19,048.261,302View SEC Filing  
6/5/2017David MainInsiderSell15,625$13.26$207,187.5077,530View SEC Filing  
1/9/2017Bros. Advisors Lp BakerMajor ShareholderBuy398,062$17.18$6,838,705.16View SEC Filing  
9/20/2016Bros. Advisors Lp BakerMajor ShareholderBuy2,783,605$12.25$34,099,161.25View SEC Filing  
3/16/2016Bros. Advisors Lp BakerMajor ShareholderBuy471,667$7.99$3,768,619.33View SEC Filing  
3/15/2016Bros. Advisors Lp BakerMajor ShareholderBuy109,912$7.98$877,097.76View SEC Filing  
1/26/2016Bros. Advisors Lp BakerMajor ShareholderBuy140,786$10.80$1,520,488.80View SEC Filing  
1/20/2016Bros. Advisors Lp BakerMajor ShareholderBuy112,034$9.48$1,062,082.32View SEC Filing  
1/19/2016Bros. Advisors Lp BakerMajor ShareholderBuy78,045$9.11$710,989.95View SEC Filing  
1/15/2016Bros. Advisors Lp BakerMajor ShareholderBuy202,623$8.28$1,677,718.44View SEC Filing  
9/10/2015Bros. Advisors Lp BakerMajor ShareholderBuy2,480,032$15.50$38,440,496.00View SEC Filing  
8/24/2015David Chilton MitchellVPBuy3,575$17.81$63,670.751,600View SEC Filing  
8/12/2015Kamran AlamCFOSell29,079$18.67$542,904.93View SEC Filing  
8/12/2015Lloyd MackenzieVPSell35,887$18.67$670,010.29View SEC Filing  
12/17/2014& Johnson JohnsonMajor ShareholderSell8,100$7.62$61,722.00View SEC Filing  
12/12/2014& Johnson JohnsonMajor ShareholderSell5,000$7.51$37,550.00View SEC Filing  
12/10/2014& Johnson JohnsonMajor ShareholderSell8,300$7.72$64,076.00View SEC Filing  
12/9/2014& Johnson JohnsonMajor ShareholderSell5,000$7.73$38,650.00View SEC Filing  
12/8/2014& Johnson JohnsonMajor ShareholderSell2,000$7.69$15,380.00View SEC Filing  
12/5/2014& Johnson JohnsonMajor ShareholderSell15,900$7.76$123,384.00View SEC Filing  
12/1/2014& Johnson JohnsonMajor ShareholderSell1,200$7.54$9,048.00View SEC Filing  
11/26/2014& Johnson JohnsonMajor ShareholderSell2,000$7.75$15,500.00View SEC Filing  
11/24/2014& Johnson JohnsonMajor ShareholderSell9,500$8.14$77,330.00View SEC Filing  
3/12/2014Pfizer IncMajor ShareholderBuy272,727$11.00$2,999,997.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Aquinox Pharmaceuticals (NASDAQ AQXP) News Headlines

Source:
DateHeadline
Aquinox Pharmaceuticals (AQXP) Given a $22.00 Price Target by Canaccord Genuity AnalystsAquinox Pharmaceuticals (AQXP) Given a $22.00 Price Target by Canaccord Genuity Analysts
www.americanbankingnews.com - April 12 at 11:27 AM
Aquinox Pharmaceuticals (AQXP) Lowered to "Sell" at BidaskClubAquinox Pharmaceuticals (AQXP) Lowered to "Sell" at BidaskClub
www.americanbankingnews.com - April 10 at 11:28 AM
Aquinox Pharmaceuticals Inc (AQXP) Given Average Recommendation of "Hold" by BrokeragesAquinox Pharmaceuticals Inc (AQXP) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 4 at 1:47 PM
ValuEngine Upgrades Aquinox Pharmaceuticals (AQXP) to HoldValuEngine Upgrades Aquinox Pharmaceuticals (AQXP) to Hold
www.americanbankingnews.com - April 3 at 7:35 PM
Free Research Report as Zoetis’ Quarterly Revenues Gained 13% and Adjusted EPS Soared 47%Free Research Report as Zoetis’ Quarterly Revenues Gained 13% and Adjusted EPS Soared 47%
finance.yahoo.com - March 26 at 8:22 AM
Aquinox Pharmaceuticals (AQXP) Upgraded to "Sell" by BidaskClubAquinox Pharmaceuticals (AQXP) Upgraded to "Sell" by BidaskClub
www.americanbankingnews.com - March 25 at 3:47 PM
Aquinox to Present at the 17th Annual Needham Healthcare ConferenceAquinox to Present at the 17th Annual Needham Healthcare Conference
finance.yahoo.com - March 21 at 5:38 PM
Aquinox Pharmaceuticals Inc (AQXP) COO Sells $19,048.26 in StockAquinox Pharmaceuticals Inc (AQXP) COO Sells $19,048.26 in Stock
www.americanbankingnews.com - March 19 at 8:30 PM
Aquinox Pharmaceuticals (AQXP) Stock Rating Lowered by Zacks Investment ResearchAquinox Pharmaceuticals (AQXP) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 16 at 5:06 PM
Aquinox Pharmaceuticals Inc to Post FY2018 Earnings of ($2.27) Per Share, Cantor Fitzgerald Forecasts (AQXP)Aquinox Pharmaceuticals Inc to Post FY2018 Earnings of ($2.27) Per Share, Cantor Fitzgerald Forecasts (AQXP)
www.americanbankingnews.com - March 16 at 10:42 AM
Aquinox Pharmaceuticals Inc (AQXP) to Post FY2019 Earnings of ($1.59) Per Share, Cantor Fitzgerald ForecastsAquinox Pharmaceuticals Inc (AQXP) to Post FY2019 Earnings of ($1.59) Per Share, Cantor Fitzgerald Forecasts
www.americanbankingnews.com - March 15 at 12:58 PM
Aquinox Pharmaceuticals Announces Year End 2017 Financial Results - GlobeNewswire (press release)Aquinox Pharmaceuticals Announces Year End 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - March 14 at 8:31 AM
Aquinox Pharmaceuticals (AQXP) Issues  Earnings ResultsAquinox Pharmaceuticals (AQXP) Issues Earnings Results
www.americanbankingnews.com - March 13 at 10:20 AM
Cantor Fitzgerald Remains Bullish on Aquinox Pharma (AQXP) Following 4Q - StreetInsider.comCantor Fitzgerald Remains Bullish on Aquinox Pharma (AQXP) Following 4Q - StreetInsider.com
www.streetinsider.com - March 13 at 8:25 AM
BRIEF-Aquinox Pharmaceuticals Inc Files For Mixed Shelf Offering Of Up To $250 Million - SEC FilingBRIEF-Aquinox Pharmaceuticals Inc Files For Mixed Shelf Offering Of Up To $250 Million - SEC Filing
www.reuters.com - March 12 at 6:40 PM
Aquinox Pharmaceuticals Announces Year End 2017 Financial ResultsAquinox Pharmaceuticals Announces Year End 2017 Financial Results
finance.yahoo.com - March 12 at 6:40 PM
Aquinox Pharmaceuticals, Inc. to Host Earnings CallAquinox Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - March 12 at 6:40 PM
Aquinox reports 4Q lossAquinox reports 4Q loss
finance.yahoo.com - March 12 at 6:40 PM
Morning News Call - Canada, March 12Morning News Call - Canada, March 12
finance.yahoo.com - March 12 at 9:01 AM
Aquinox Pharmaceuticals Inc (AQXP) Given Average Rating of "Hold" by AnalystsAquinox Pharmaceuticals Inc (AQXP) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - March 10 at 1:53 PM
Aquinox Pharmaceuticals Inc (AQXP) Shares Bought by Emory UniversityAquinox Pharmaceuticals Inc (AQXP) Shares Bought by Emory University
www.americanbankingnews.com - March 4 at 2:59 PM
Aquinox Pharmaceuticals (AQXP) to Release Quarterly Earnings on WednesdayAquinox Pharmaceuticals (AQXP) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - February 28 at 1:24 AM
Zacks: Brokerages Expect Aquinox Pharmaceuticals Inc (AQXP) to Post -$0.65 Earnings Per ShareZacks: Brokerages Expect Aquinox Pharmaceuticals Inc (AQXP) to Post -$0.65 Earnings Per Share
www.americanbankingnews.com - February 19 at 5:16 PM
Aquinox Pharmaceuticals (AQXP) Lifted to Hold at BidaskClubAquinox Pharmaceuticals (AQXP) Lifted to Hold at BidaskClub
www.americanbankingnews.com - February 18 at 3:32 PM
Aquinox Pharma (AQXP) Presents At Leerink Partners 7th Annual Global Healthcare Conference - SlideshowAquinox Pharma (AQXP) Presents At Leerink Partners 7th Annual Global Healthcare Conference - Slideshow
seekingalpha.com - February 16 at 5:18 PM
Analyzing Eli Lilly and (LLY) and Aquinox Pharmaceuticals (AQXP)Analyzing Eli Lilly and (LLY) and Aquinox Pharmaceuticals (AQXP)
www.americanbankingnews.com - February 16 at 1:18 AM
Aquinox Pharmaceuticals (AQXP) Buy Rating Reiterated at Cantor FitzgeraldAquinox Pharmaceuticals' (AQXP) Buy Rating Reiterated at Cantor Fitzgerald
www.americanbankingnews.com - February 12 at 12:32 AM
Aquinox Provides Enrollment Update for LEADERSHIP 301 Clinical Trial of RosiptorAquinox Provides Enrollment Update for LEADERSHIP 301 Clinical Trial of Rosiptor
finance.yahoo.com - February 9 at 9:49 AM
Aquinox Pharmaceuticals (AQXP) Earns Buy Rating from Analysts at GuggenheimAquinox Pharmaceuticals (AQXP) Earns Buy Rating from Analysts at Guggenheim
www.americanbankingnews.com - February 8 at 8:54 PM
Zacks: Brokerages Anticipate Aquinox Pharmaceuticals Inc (AQXP) Will Announce Earnings of -$0.65 Per ShareZacks: Brokerages Anticipate Aquinox Pharmaceuticals Inc (AQXP) Will Announce Earnings of -$0.65 Per Share
www.americanbankingnews.com - February 2 at 5:10 PM
Cara Therapeutics’ Collaboration AgreementsCara Therapeutics’ Collaboration Agreements
finance.yahoo.com - February 2 at 9:19 AM
Comparing Cara Therapeutics’ Financial PerformanceComparing Cara Therapeutics’ Financial Performance
finance.yahoo.com - February 2 at 9:19 AM
Aquinox Pharmaceuticals (AQXP) versus Celsius (CELH) Critical AnalysisAquinox Pharmaceuticals (AQXP) versus Celsius (CELH) Critical Analysis
www.americanbankingnews.com - January 26 at 1:30 PM
Aquinox to Host Analyst and Investor Event in New York CityAquinox to Host Analyst and Investor Event in New York City
finance.yahoo.com - January 26 at 9:08 AM
Aquinox Pharmaceuticals Inc (AQXP) Receives Average Recommendation of "Hold" from BrokeragesAquinox Pharmaceuticals Inc (AQXP) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 19 at 3:40 PM
Aquinox Pharmaceuticals (AQXP) Downgraded to "Hold" at Zacks Investment ResearchAquinox Pharmaceuticals (AQXP) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 12 at 4:28 PM
Zacks Investment Research Upgrades Aquinox Pharmaceuticals (AQXP) to "Buy"Zacks Investment Research Upgrades Aquinox Pharmaceuticals (AQXP) to "Buy"
www.americanbankingnews.com - January 9 at 6:26 PM
 Analysts Expect Aquinox Pharmaceuticals Inc (AQXP) Will Post Earnings of -$0.65 Per Share Analysts Expect Aquinox Pharmaceuticals Inc (AQXP) Will Post Earnings of -$0.65 Per Share
www.americanbankingnews.com - December 31 at 1:30 AM
Aquinox Pharmaceuticals Inc (AQXP) Receives Consensus Recommendation of "Hold" from AnalystsAquinox Pharmaceuticals Inc (AQXP) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - December 25 at 1:52 PM
Critical Comparison: Lannett (LCI) & Aquinox Pharmaceuticals (AQXP)Critical Comparison: Lannett (LCI) & Aquinox Pharmaceuticals (AQXP)
www.americanbankingnews.com - December 18 at 3:28 AM
Reviewing Aquinox Pharmaceuticals (AQXP) and BioLife Solutions (BLFS)Reviewing Aquinox Pharmaceuticals (AQXP) and BioLife Solutions (BLFS)
www.americanbankingnews.com - December 15 at 5:28 PM
Aquinox Pharma (AQXP) Promotes Lloyd Mackenzie to COO - StreetInsider.comAquinox Pharma (AQXP) Promotes Lloyd Mackenzie to COO - StreetInsider.com
www.streetinsider.com - December 15 at 11:54 AM
Aquinox Promotes Lloyd Mackenzie to Chief Operating Officer and Vice President, R&D OperationsAquinox Promotes Lloyd Mackenzie to Chief Operating Officer and Vice President, R&D Operations
finance.yahoo.com - December 15 at 11:53 AM
Aquinox Pharma up 16% premarket on FDA advisory committee vote on IC/BPS studies - Seeking AlphaAquinox Pharma up 16% premarket on FDA advisory committee vote on IC/BPS studies - Seeking Alpha
seekingalpha.com - December 12 at 12:02 PM
Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) - GlobeNewswire (press release)Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) - GlobeNewswire (press release)
globenewswire.com - December 9 at 3:40 PM
Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
www.nasdaq.com - December 8 at 11:37 AM
Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
finance.yahoo.com - December 8 at 11:37 AM
Aquinox Pharmaceuticals: Expecting A Rebound In 2018 - Seeking AlphaAquinox Pharmaceuticals: Expecting A Rebound In 2018 - Seeking Alpha
seekingalpha.com - November 22 at 4:38 PM
Aquinox Pharmaceuticals, Inc. (AQXP) Stock Rating Reaffirmed by Canaccord GenuityAquinox Pharmaceuticals, Inc. (AQXP) Stock Rating Reaffirmed by Canaccord Genuity
www.americanbankingnews.com - November 21 at 3:24 PM
FY2017 EPS Estimates for Aquinox Pharmaceuticals, Inc. (AQXP) Lifted by Cantor FitzgeraldFY2017 EPS Estimates for Aquinox Pharmaceuticals, Inc. (AQXP) Lifted by Cantor Fitzgerald
www.americanbankingnews.com - November 15 at 7:32 AM

SEC Filings

Aquinox Pharmaceuticals (NASDAQ:AQXP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Aquinox Pharmaceuticals (NASDAQ:AQXP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Aquinox Pharmaceuticals (NASDAQ AQXP) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.